Skip to main content
DIRUI INDUSTRIAL CO.,LTD. logo

DIRUI INDUSTRIAL CO.,LTD. — Investor Relations & Filings

Ticker · 300396 ISIN · CNE100001XS7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,690 across all filing types
Latest filing 2015-06-15 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300396

About DIRUI INDUSTRIAL CO.,LTD.

https://www.dirui.com.cn

DIRUI INDUSTRIAL CO.,LTD. specializes in the research, development, manufacturing, and distribution of medical laboratory instruments and diagnostic reagents. The company provides comprehensive solutions for in-vitro diagnostics (IVD), focusing on several key clinical areas including urinalysis, biochemistry, hematology, and chemiluminescence immunoassay. Its product portfolio features high-throughput automated analyzers and integrated laboratory systems designed to enhance diagnostic efficiency and accuracy. DIRUI serves a global market, providing medical institutions and laboratories with a wide range of diagnostic tools, from urine sediment analysis to vaginal secretion testing. The company emphasizes technological innovation and quality control to support clinical decision-making and patient care through reliable laboratory automation and standardized testing protocols.

Recent filings

Filing Released Lang Actions
关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun Dirui Medical Technology Co., Ltd. regarding abnormal stock price fluctuations. It details the company's verification of the situation, explanations about a major asset purchase plan, and risk warnings related to the transaction. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure about stock trading anomalies and related corporate actions. It is not an annual report, earnings release, or management report. It is also not a report publication announcement since it contains substantive information about the stock price anomaly and the asset purchase plan. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about stock trading irregularities and corporate disclosures that do not fit other specific categories.
2015-06-15 Chinese
公司关于深圳证券交易所《关于对长春迪瑞医疗科技股份有限公司的问询函》相关问题的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding a major asset purchase by Changchun Dirui Medical Technology Co., Ltd. It includes extensive financial and operational details about the acquisition target, Ningbo Ruiyuan, valuation methods, performance commitments, and changes in the use of proceeds from the company's initial public offering. The document references a "重组报告书" (restructuring report or major asset purchase report) and contains detailed financial data, valuation analysis, and legal opinions related to the transaction. This type of document is characteristic of a Major Asset Purchase Report or a detailed transaction disclosure related to a significant acquisition. Given the content focuses on a major asset purchase and related financial and legal disclosures, the most appropriate classification is "Capital/Financing Update (CAP)" as it updates on company financing activities and capital structure changes related to the acquisition. The document is lengthy and substantive, not merely an announcement or a brief summary, so it is not an RPA or RNS. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a proxy or voting result. Therefore, the best fit is CAP.
2015-06-11 Chinese
第二届董事会第十二次临时会议决议的公告
M&A Activity Classification · 95% confidence The document is an announcement of resolutions passed at a board of directors meeting of Changchun Dirui Medical Technology Co., Ltd. It details the approval of a revised draft report on a major asset purchase and mentions the upcoming extraordinary general meeting to consider this matter. The document includes voting results and procedural compliance statements. It does not contain full financial statements or detailed financial analysis, nor is it a transcript or presentation. It is a formal announcement of board decisions related to a significant transaction, which aligns with the category of M&A Activity announcements. The document length is short (1096 characters), and it is not merely announcing the publication of a report but is itself a formal board resolution announcement related to a merger/acquisition activity.
2015-06-11 Chinese
东北证券股份有限公司关于公司重大资产购买之补充独立财务顾问报告（一）
Audit Report / Information Classification · 95% confidence The document is titled as a "Supplementary Independent Financial Advisor Report (I)" related to a "Major Asset Purchase" by Changchun Dirui Medical Technology Co., Ltd. It is prepared by an independent financial advisor (Northeast Securities Co., Ltd.) and addresses detailed financial and legal due diligence, valuation, and fairness opinions regarding a significant asset acquisition. The content includes detailed financial analysis, valuation multiples, legal review of agreements, and funding source disclosures. The document is a formal advisory report prepared for regulatory and shareholder review in connection with a major asset acquisition transaction. It is not an announcement, transcript, or summary but a comprehensive advisory report. This fits the category of an Audit Report / Information (AR) as it is a standalone financial advisory report related to a transaction, including valuation and fairness opinions, prepared by an independent financial advisor, distinct from a full annual report or earnings release. FY 2014
2015-06-11 Chinese
关于重大资产购买报告书（草案）的修订说明
Capital/Financing Update Classification · 95% confidence The document is a detailed explanation and revision note regarding a major asset purchase report (重大资产购买报告书) by Changchun Dirui Medical Technology Co., Ltd. It includes extensive financial and operational details about the acquisition, valuation methods, funding sources including IPO proceeds, and legal and financial advisor opinions. The content focuses on the asset purchase transaction, valuation, funding changes, and related disclosures. It is not a full annual or quarterly report, nor is it a simple announcement or certification. The document is a comprehensive report related to a significant capital transaction (major asset purchase). This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including major asset acquisitions and related financial disclosures.
2015-06-11 Chinese
重大资产购买报告书（修订稿）摘要
Capital/Financing Update Classification · 95% confidence The document is titled as a "重大资产购买报告书" which translates to "Major Asset Purchase Report" or "Significant Asset Acquisition Report." It details a transaction involving the acquisition of 51% equity in a company, including transaction parties, pricing, funding sources, valuation methods, approvals, risks, and impact on the listed company. The document includes detailed financial data, legal commitments, risk disclosures, and regulatory compliance information related to a major asset purchase. It is not a general annual or quarterly report, nor is it an earnings release or a simple announcement. It is a comprehensive report on a significant asset acquisition, which aligns with the category of Capital/Financing Update (CAP) filings that cover company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and transaction details, not just an announcement or summary. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2015-06-11 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.